Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Free Cash Flow: 2019-2024

Historic Free Cash Flow for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$34.0 million.

  • GeneDx Holdings' Free Cash Flow rose 284.09% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 125.99%. This contributed to the annual value of -$34.0 million for FY2024, which is 81.67% up from last year.
  • As of FY2024, GeneDx Holdings' Free Cash Flow stood at -$34.0 million, which was up 81.67% from -$185.4 million recorded in FY2023.
  • GeneDx Holdings' 5-year Free Cash Flow high stood at -$34.0 million for FY2024, and its period low was -$326.3 million during FY2022.
  • Over the past 3 years, GeneDx Holdings' median Free Cash Flow value was -$185.4 million (recorded in 2023), while the average stood at -$181.9 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 282.44% in 2020, then spiked by 81.67% in 2024.
  • Yearly analysis of 5 years shows GeneDx Holdings' Free Cash Flow stood at -$117.2 million in 2020, then plummeted by 72.17% to -$201.8 million in 2021, then slumped by 61.69% to -$326.3 million in 2022, then spiked by 43.19% to -$185.4 million in 2023, then surged by 81.67% to -$34.0 million in 2024.